1
|
Sokolovskaya I, Prybora N, Valentyna Nechyporenko VN, Pozdniakova O, Hordiienko N, Nechyporenko K, Siliavina Y, Mavrin V, Kotuza A, Kliusov O, Kryachok I, Tytorenko I, Zub V, Yanitka L, Hordienko N, Kudinova M, Mamedli Z, Hordiienko L, Kmetyuk Y, Sprynchuk N. Assessment of the State of Platelet Haemostasis and Adhesive - Aggregation Properties of Platelets as a Factor of Increasing the Tendency to Thrombosis in Chronic Inflammation. Fr Ukr J Chem 2022. [DOI: 10.17721/fujcv10i2p22-36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/08/2023] Open
Abstract
In recent decades, considerable progress has been made in understanding the functional mechanisms of platelets and the correction of platelet haemostasis. Platelets are considered the most important participants in both the normal and pathological thrombotic processes characteristic of a variety of diseases and conditions. Alterations in various limbs of haemostasis are found in many somatic diseases (atherosclerosis, coronary heart disease, stroke), surgical procedures, oncological and immunological diseases. Inflammation underlies most diseases and remains an urgent problem in medicine. In the leukocyte infiltration of the inflammatory focus, the mechanism of its self-preservation is of great importance. The activation of haematopoiesis during inflammation is triggered by factors released by stimulated leukocytes of the focus and peripheral blood. Therefore, the problem of the state of the haemostasis system should be the focus of constant attention of clinicians, and with the help of laboratory monitoring of the state of the haemostasis system, it is possible to carry out drug correction of the haemocoagulation potential.
Collapse
|
2
|
Abramenko I, Bilous N, Chumak A, Kryachok I, Fedorenko Z, Martina Z, Dyagil I. The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients. Leuk Res 2021; 110:106686. [PMID: 34492598 DOI: 10.1016/j.leukres.2021.106686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Revised: 07/30/2021] [Accepted: 08/15/2021] [Indexed: 11/19/2022]
Abstract
The mutational status of the variable region of the immunoglobulin heavy chain (IGHV) genes remains the most significant prognostic factor in chronic lymphocytic leukemia (CLL) patients. However, the groups of mutated (M) and unmutated (UM) patients are also heterogeneous, and additional markers are used for a more accurate prognosis. The aim of our work was to determine the prognostic value of the signs of antigen selection determined by BASELINe statistics in M IGHV sequences of CLL patients. Clinical data, IGHV gene configuration, TP53, NOTCH1, SF3B1 mutations were analyzed in 127 CLL patients with M IGHV sequences. The median OS of patients with negative selection in the framework regions (FWRs) of IGHV genes was 120 months compared to 202 month in other CLL patients (P = 0.016). In multivariate Cox regression analysis Binet stage C vs A + B (P < 0.0001), SF3B1 mutations (P < 0.0001), negative selection in the FWRs (HR P = 0.007), and age ≥65 years (P = 0.034) were powerful adverse prognostic factors for OS in CLL patients with M IGHV genes. These preliminary data suggest that the signs of antigen-driven selection may be used as a prognostic factor in CLL patients with M IGHV genes in combination with other markers.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor/genetics
- Female
- Follow-Up Studies
- Humans
- Immunoglobulin Heavy Chains/genetics
- Immunoglobulin Variable Region/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Male
- Middle Aged
- Mutation
- Prognosis
- Survival Rate
Collapse
Affiliation(s)
- Iryna Abramenko
- Department of Clinical Immunology, National Research Center for Radiation Medicine, Academy of Medical Sciences of Ukraine, 119/121 Prospect Peremohy Str., 03115, Kyiv, Ukraine.
| | - Nadia Bilous
- Department of Clinical Immunology, National Research Center for Radiation Medicine, Academy of Medical Sciences of Ukraine, 119/121 Prospect Peremohy Str., 03115, Kyiv, Ukraine.
| | - Anatoliy Chumak
- Department of Clinical Immunology, National Research Center for Radiation Medicine, Academy of Medical Sciences of Ukraine, 119/121 Prospect Peremohy Str., 03115, Kyiv, Ukraine.
| | - Iryna Kryachok
- Department of Oncohematology, National Cancer Institute, 33/43 Lomonosova Str., 03022, Kyiv, Ukraine.
| | - Zoya Fedorenko
- National Cancer Registry, National Cancer Institute, 33/43 Lomonosova Str., 03022, Kyiv, Ukraine.
| | - Zoya Martina
- Department of Hematology, National Research Center for Radiation Medicine, Academy of Medical Sciences of Ukraine, 119/121 Prospect Peremohy Str., 03115, Kyiv, Ukraine.
| | - Iryna Dyagil
- Department of Hematology, National Research Center for Radiation Medicine, Academy of Medical Sciences of Ukraine, 119/121 Prospect Peremohy Str., 03115, Kyiv, Ukraine.
| |
Collapse
|
3
|
Federico M, Chiattone CS, Prince HM, Pavlovsky A, Manni M, Civallero M, Skrypets T, De Souza CA, Hawkes EA, Fiad L, Lymboussakis A, Tomuleasa C, Nair R, Pereira J, Pereyra P, Minoia C, Kryachok I, de Castro NS, Advani RH, Luminari S. SUBTYPES OF MATURE T AND NK CELL LYMPHOMAS ACCORDING TO 2016 WHO CLASSIFICATION. PRELIMINARY REPORT OF THE INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0. Hematol Oncol 2021. [DOI: 10.1002/hon.135_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M Federico
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - C. S Chiattone
- Santa Casa de Sao Paulo School of Medical Sciences São Paulo Brazil
| | - H. M Prince
- Epworth Healthcare, East Melbourne Richmond Australia
| | - A Pavlovsky
- Fundaleu, Haematology Buenos Aires Argentina
| | - M Manni
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - M Civallero
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - T Skrypets
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | | | - E. A Hawkes
- Lymphoma and Related Diseases Registry School of Public Health and Preventive Medicine Monash University and Olivia Newton John Cancer Research Institute Austin Health, Melbourne Australia
| | - L Fiad
- Hospital Italiano La Plata Department of Hematology and Oncology Buenos Aires Argentina
| | - A Lymboussakis
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - C Tomuleasa
- Ion Chiricuta Oncology Institute Department of Hematology Cluj Napoca Romania
| | - R Nair
- TATA Medical Center, Clinical Haematology Oncology Kolkata India
| | - J Pereira
- Universidade de São Paulo Hospital das Clínicas da Faculdade de Medicina São Paulo Brazil
| | - P Pereyra
- Hospital Nacional Dr. Prof. Alejandro Posadas Hematology Buenos Aires Argentina
| | - C Minoia
- IRCCS Cancer Institute "Giovanni Paolo II" Haematology Unit Bari Italy
| | - I Kryachok
- National Cancer Institute Oncohematology Department Kiev Ukraine
| | - N. S de Castro
- Hospital de Cancer de Barretos, Hematology, Barretos São Paulo Brazil
| | - R. H Advani
- Stanford Cancer Center Blood and Marrow Transplant Program, Stanford California USA
| | - S Luminari
- Azienda Unità Sanitaria Locale IRCCS, Arcispedale Santa Maria Nuova IRCCS, Hematology Unit and University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Reggio Emilia Italy
| |
Collapse
|
4
|
Martelli M, Zucca E, Botto B, Kryachok I, Ceriani L, Balzarotti M, Tucci A, Cabras MG, Zilioli VR, Rusconi C, Angrilli F, Arcaini L, Iwanicka AD, Ferreri A, Merli F, Zhao W, Hodgson D, Ionescu C, Fosså A, Cwynarski K, Mikhaeel G, Jerkeman M, Janikova A, Hüttmann A, Ciccone G, Metser U, Barrington S, Malkowski B, Versari A, Esposito F, Cozens K, Ielmini N, Ricardi R, Cavalli F, Johnson P, Davies A. IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.49_2879] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
5
|
Dimopoulos MA, Delimpasi S, Simonova M, Spicka I, Pour L, Kryachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Kaplan P, Hajek R, Reuben B, Dolai TK, Sinha DK, Arazy M, Richardson PG, Bahlis NJ, Grosicki S. Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.8501] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8501 Background: Selinexor is an oral, selective inhibitor of XPO1-mediated nuclear export, leading to the reactivation of tumor suppressor proteins. In a phase 1b/2 study, the combination of once weekly (QW) selinexor with bortezomib and dexamethasone (SVd) was well tolerated with anti-MM activity in patients (pts) with PI-sensitive and PI-refractory disease. While twice weekly (BIW) bortezomib in combination therapy is efficacious, prolonged use is limited due to peripheral neuropathy (PN, 50-60%). The BOSTON study was designed to determine if SVd improves progression free survival (PFS), overall response rates (ORR) and reduces the rate of PN vs Vd. Methods: BOSTON is a global, phase 3, randomized study of QW SVd vs BIW Vd after 1-3 prior anti-MM regimens. The primary endpoint is PFS. Secondary endpoints include ORR, overall survival (OS) and PN (rates and EORTC QLQ-CIPN20 outcomes). Randomization is stratified by treatment with prior PI therapies, number of prior anti-MM regimens (1 vs > 1), and Revised International Staging System (R-ISS; Stage III vs I or II). Following confirmation of progressive disease, pts on Vd could cross over to either: 1) SVd for pts able to tolerate continued bortezomib or 2) selinexor and dexamethasone for pts with bortezomib intolerance. Results:402 pts were enrolled; 195 and 207 to SVd and Vd, respectively. Median age was 67 (range: 38-90). Most (59.6%) pts were > 65 years and 57.1% were male. R-ISS stage at the time of MM diagnosis was III for 18.5% of pts. Baseline characteristics were balanced across the 2 arms. SVd significantly prolonged PFS vs Vd (median 13.93 vs 9.46 months, HR = 0.70, P = 0.0066). SVd was associated with a significantly higher ORR (76.4% vs 62.3%, P = 0.0012). Median OS was not reached on SVd vs 25 months on Vd (P = 0.28). Most frequent treatment-related adverse events (grade ≥3) for SVd vs Vd were thrombocytopenia (35.9% vs 15.2%), fatigue (11.3% vs 0.5%) and nausea (7.7% vs 0%). Clinically important differences were reported on the motor, autonomic and sensory scales on CIPN20. PN rates (grade ≥2) were significantly lower with SVd vs Vd (21.0% vs 34.3%, P = 0.0013). Conclusions: BOSTON is the first phase 3 study to evaluate the clinical benefit of SVd for relapsed/refractory MM. The study met the primary endpoint: once weekly SVd significantly improved PFS and ORR compared to twice weekly Vd. Rates of PN were significantly reduced with numerically fewer deaths on SVd vs Vd. Full dataset will be presented at the meeting. Clinical trial information: NCT03110562 .
Collapse
Affiliation(s)
| | | | - Maryana Simonova
- Institute of Blood Pathology & Transfusion Medicine of National Academy of Medical Sciences of Ukraine, Lviv, Ukraine
| | - Ivan Spicka
- Charles University and General Hospital, Prague, Czech Republic
| | - Ludek Pour
- Fakultní Nemocnice Brno, Brno, Czech Republic
| | | | - Maria Gavriatopoulou
- Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - Halyna Pylypenko
- Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine
| | | | - Xavier Leleu
- Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France
| | - Vadim Doronin
- City Clinical Hospital #40, Moscow, Russian Federation
| | | | - Roman Hajek
- Department of Hemato-oncology, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic
| | - Benjamin Reuben
- Kings College Hospital NHS Foundation Trust, London, United Kingdom
| | | | - Dinesh Kumar Sinha
- State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India
| | | | | | - Nizar J. Bahlis
- University of Calgary, Charbonneau Cancer Research Institute, Calgary, AB, Canada
| | | |
Collapse
|
6
|
Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson N, Melnichenko V, Fogliatto LM, Goncalves I, de Oliveira J, Buccheri V, Perini GF, Goldschmidt N, Alekseev S, Kryachok I, Sekiguchi N, Zhu Y, Nahar A, Marinello P, Zinzani PL. KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL). J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.8005] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
8005 Background: PD-1 blockade via pembro monotherapy showed antitumor activity in R/R cHL. KEYNOTE-204 (NCT02684292) was a randomized, international, open-label, phase III study of pembro vs BV in R/R cHL. Methods: Patients (pts) were aged ≥18 y, were post−autologous stem cell transplant (auto-SCT) or ineligible for auto-SCT, and had measurable disease and ECOG PS 0 or 1. BV-naive and BV-exposed pts were eligible. Pts were randomized 1:1 to pembro 200 mg IV Q3W or BV 1.8 mg/kg IV Q3W and stratified by prior auto-SCT (yes vs no) and status after 1L therapy (primary refractory vs relapsed <12 mo vs relapsed ≥12 mo after end of 1L therapy). Primary end points: PFS by blinded independent central review (BICR) per International Working Group (IWG) criteria including clinical and imaging data after auto-SCT or allogeneic SCT (allo-SCT) and OS. Key secondary end points: PFS excluding clinical and imaging data after auto-SCT or allo-SCT (PFS-secondary), and ORR by BICR per IWG, PFS by investigator review per IWG, and safety. Exploratory end point: DOR by BICR per IWG. Results: 304 pts were randomized and 300 were treated (148, pembro; 152, BV); 256 discontinued. Median (range) follow-up: 24.7 (0.6-42.3) mo. 15 pts were BV exposed. Median (range) time on treatment was 305.0 (1-814) and 146.5 (1-794) days with pembro and BV, respectively. Statistically significant improvement was observed with pembro vs BV for primary PFS analysis (HR 0.65 [95% CI 0.48-0.88; P =0.00271]; median 13.2 vs 8.3 mo); 12-mo PFS rates were 53.9% vs 35.6%, respectively. Benefit was observed in all subgroups tested, including pts with no auto-SCT (HR=0.61), primary refractory disease (HR=0.52), prior BV (HR=0.34) and BV naive (HR=0.67). Significant improvement in PFS-secondary was observed with pembro vs BV (HR 0.62 [95% CI 0.46-0.85]; median 12.6 vs 8.2 mo). Per investigator assessment, PFS was longer with pembro vs BV (HR 0.49 [95% CI 0.36-0.67]; median 19.2 vs 8.2 mo). ORR was 65.6% for pembro and 54.2% for BV; CR rates were 24.5% and 24.2%, respectively. Median (range) DOR was 20.7 mo (0.0+ to 33.2+) for pembro and 13.8 mo (0.0+ to 33.9+) for BV. Grade 3-5 TRAEs: 19.6% of pts with pembro and 25.0% with BV. One death due to TRAE occurred with pembro (pneumonia). Conclusions: In pts with R/R cHL, pembro was superior to BV and demonstrated statistically significant and clinically meaningful improvement in PFS across all subgroups, with safety consistent with previous reports. Pembro monotherapy should be standard of care for this pt population with R/R/cHL. Clinical trial information: NCT02684292 .
Collapse
Affiliation(s)
| | | | - Armando Santoro
- Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy
| | | | - Robin Gasiorowski
- Concord Repatriation General Hospital, University of Sydney, Sydney, Australia
| | | | | | | | | | | | - Valeria Buccheri
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | | | | | - Sergey Alekseev
- N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russian Federation
| | | | - Naohiro Sekiguchi
- National Hospital Organization Disaster Medical Center, Tokyo, Japan
| | - Ying Zhu
- Merck & Co., Inc., Kenilworth, NJ
| | | | | | - Pier Luigi Zinzani
- Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy
| |
Collapse
|
7
|
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F, Van Hoof A, Sheliga A, Teixeira A, Tomita A, Rocafiguera AO, Suvorov A, Kuzmin A, Khojasteh A, Mezlini A, Golenkov A, Bosly A, Belch A, Van De Velde A, Illes Á, Mukhopadhyay A, Meddeb B, De Prijck B, Garichochea B, Undar B, Gabarrón C, Cao C, Souza C, Farber C, Won Suh C, Burcoveanu CI, Cebotaru CL, Truica CL, Maruyama D, Belada D, Ben Yehuda D, Udovitsa D, Dolores, Morra E, Späth-Schwalbe E, Gonzalez-Barca E, Osmanov E, Capote FJ, Offner F, Cardenas G, Heß G, Manikhas G, Babu G, Rekhtman G, Rossi G, Marques H, Bumbea H, Wang H, Huang H, Choi I, Bulavina I, Lysenko I, Avivi I, Kryachok I, Zaucha JM, Novak J, Díaz J, Demeter J, Alexeeva J, Zhu J, Vilchevskaya K, Ishizawa K, Mauricio K, Tobinai K, Ando K, Abdulkadryrov K, Shih LY, Kuzina L, Gumus M, De Wit M, Capra M, Marques M, Golubeva M, Ojeda-Uribe M, Kyselyova M, Taniwaki M, Federico M, Crump M, Baccarani M, Ogura M, Egyed M, Udvardy M, Kurosawa M, Uike N, Khuageva N, Shpilberg O, Gladkov O, Samoilova O, Serduk O, Santi P, Zachee P, Kaplan P, Stoia R, Gressin R, Arranz R, Greil R, Grosicki S, Cancelado S, Nair S, Le Gouill S, Van Steenweghen S, Yoon SS, Chuncharune S, Scheider T, Shimoyama T, Liu T, Kinoshita T, Uchida T, Bunworasate U, Vitolo U, Pavlov V, Phooshkooru VR, Lima V, Merkulov V, Nawarawong W, Hong X, Ke X, Terui Y, Tee Goh Y, Maeda Y, Shi Y, Dunaev Y, Lorie Y, Wang Z, Shen Z, Borbenyi Z, Gasztonyi Z, Masliak Z. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol 2018; 19:1449-1458. [DOI: 10.1016/s1470-2045(18)30685-5] [Citation(s) in RCA: 82] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2018] [Revised: 09/06/2018] [Accepted: 09/07/2018] [Indexed: 10/28/2022]
|
8
|
Kryachok I, Novosad O, Skrypets T, Kadnikova T, Titorenko I, Aleksik O, Filonenko K, Martynchyk A, Pastushenko Y, Stepanishina Y, Kushchevyy E, Ulianchenko K, Surkis M, Jurchishina V, Gingsburg E. Ukrainian Association for helping patients with lymphoproliferative diseases: Patients support care program. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx385.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Skrypets T, Novosad O, Pastushenko Y, Skachkova O, Gorbach O, Khranovska N, Kryachok I. Evaluation of indoleamine 2,3-dioxygenase expression (IDO), transforming growth factor beta (TGF-β) and interleukin 13 (IL13) expression on clinical outcome in patients with Hodgkin’s lymphoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx373.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Bilous N, Abramenko I, Saenko V, Chumak A, Dyagil I, Martina Z, Kryachok I. Clinical relevance of TP53 polymorphic genetic variations in chronic lymphocytic leukemia. Leuk Res 2017; 58:1-8. [DOI: 10.1016/j.leukres.2017.03.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2017] [Revised: 03/11/2017] [Accepted: 03/14/2017] [Indexed: 02/08/2023]
|
11
|
Robak T, Warzocha K, Govind Babu K, Kulyaba Y, Kuliczkowski K, Abdulkadyrov K, Loscertales J, Kryachok I, Kłoczko J, Rekhtman G, Homenda W, Błoński JZ, McKeown A, Chang CN, Bal V, Lisby S, Gupta IV, Grosicki S. Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL. Leuk Lymphoma 2016; 58:1598-1606. [DOI: 10.1080/10428194.2016.1253837] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Tadeusz Robak
- Department of Hematology, Medical University of Łódź, Copernicus Memorial Hospital, Łódź, Poland
| | - Krzysztof Warzocha
- Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
| | - K. Govind Babu
- Kidwai Memorial Institute of Oncology, Bangalore, India
- HCG Curie Centre of Oncology, Bangalore, India
| | - Yaroslav Kulyaba
- Makiivka City Hospital No. 2 of Donetsk Region, Makiivka, Ukraine
| | | | - Kudrat Abdulkadyrov
- Russian Research Institute of Hematology and Transfusiology, St. Petersburg, Russian Federation
| | | | - Iryna Kryachok
- Oncohematology Department, National Cancer Institute, Kiev, Ukraine
| | | | | | - Wojciech Homenda
- Department of Hematology, Janusz Korczak Hospital, Słupsk, Poland
| | - Jerzy Z. Błoński
- Department of Hematology, Medical University of Łódź, Copernicus Memorial Hospital, Łódź, Poland
| | - Astrid McKeown
- Novartis Pharmaceuticals Corporation, Uxbridge, United Kingdom
| | - Chai-Ni Chang
- Novartis Pharmaceuticals Corporation, Research Triangle Park, NC, USA
| | - Vasudha Bal
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | | | - Ira V. Gupta
- Novartis Pharmaceuticals Corporation, King of Prussia, PA, USA
| | - Sebastian Grosicki
- Department of Cancer Prevention, Faculty of Public Health, Medical University of Silesia, Katowice, Poland
| |
Collapse
|
12
|
Robak T, Warzocha K, Govind Babu K, Kulyaba Y, Kuliczkowski K, Abdulkadyrov K, Loscertales J, Kryachok I, Kłoczko J, Rekhtman G, Homenda W, Błoński JZ, McKeown A, Gorczyca MM, Carey JL, Chang CN, Lisby S, Gupta IV, Grosicki S. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma 2016; 58:1084-1093. [PMID: 27731748 DOI: 10.1080/10428194.2016.1233536] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
In this multicenter, open-label, phase III study, patients with relapsed chronic lymphocytic leukemia (CLL) were randomized (1:1) to receive ofatumumab plus fludarabine and cyclophosphamide (OFA + FC) or FC alone; the primary endpoint being progression-free survival (PFS) assessed by an independent review committee (IRC). Between March 2009 and January 2012, 365 patients were randomized (OFA + FC: n = 183; FC: n = 182). Median IRC-assessed PFS was 28.9 months with OFA + FC versus 18.8 months with FC (hazard ratio = 0.67; 95% confidence interval, 0.51-0.88; p = .0032). Grade ≥3 adverse events (≤60 days after last dose) were reported in 134 (74%) OFA + FC-treated patients compared with 123 (69%) FC-treated patients. Of these, neutropenia was the most common (89 [49%] vs. 64 [36%]). OFA + FC improved PFS with manageable safety for patients with relapsed CLL compared with FC alone, thus providing an alternative treatment option for patients with relapsed CLL. TRIAL REGISTRATION www.clinicaltrials.gov (NCT00824265).
Collapse
Affiliation(s)
- Tadeusz Robak
- a Department of Hematology , Medical University of Lodz and Copernicus Memorial Hospital , Lodz , Poland
| | - Krzysztof Warzocha
- b Department of Hematology , Institute of Hematology and Transfusion Medicine , Warsaw , Poland
| | - K Govind Babu
- c Kidwai Memorial Institute of Oncology , Bangalore , India.,d HCG Curie Centre of Oncology , Bangalore , India
| | - Yaroslav Kulyaba
- e Makiivka City Hospital #2 of Donetsk Region , Makiivka , Ukraine
| | | | - Kudrat Abdulkadyrov
- g Russian Research Institute of Hematology and Transfusiology , St. Petersburg , Russia
| | | | - Iryna Kryachok
- i Oncohematology Department , National Cancer Institute , Kiev , Ukraine
| | | | | | - Wojciech Homenda
- l Department of Hematology , Janusz Korczak Hospital , Słupsk , Poland
| | - Jerzy Z Błoński
- a Department of Hematology , Medical University of Lodz and Copernicus Memorial Hospital , Lodz , Poland
| | | | | | | | - Chai-Ni Chang
- o Novartis, Research Triangle Park , Durham , NC , USA
| | | | | | - Sebastian Grosicki
- r Department of Cancer Prevention, Faculty of Public Heath , Medical University of Silesia , Katowice , Poland
| |
Collapse
|
13
|
Kryachok I, Martynchyk A, Filonenko K, Grabovoy A, Antoniuk S, Tytorenko I, Novosad O, Kadnikova T, Aleksik O, Stepanishyna I. The predictive value of immunohistochemical expression of Bcl-2, Bcl-6, MUM1, CD10 and CD30 in patients with diffuse large cell lymphoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw375.18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
14
|
Kryachok I, Stepanishyna I, Tytorenko I, Martynchyk A, Filonenko K, Novosad O, Kadnikova T, Pastushenko I, Kushchevyy Y, Skrypets T, Aleksyk O, Ulianchenko K. R-da-EPOCH vs R-CHOP in patients with primary mediastinal large B-cell lymphoma: Results of randomised (prospective) multicenter study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw375.04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Kryachok I, Skrypets T, Novosad O, Khranovska N, Skachkova O, Ulianchenko K, Martynchyk A, Tytorenko I, Filonenko K, Stepanishyna I, Svergun N, Gorbach O, Nevdakh O. The role of indoleamine 2,3-dioxygenase expression in diffuse large B-cell lymphoma prognosis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw375.17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Österborg A, Udvardy M, Zaritskey A, Andersson PO, Grosicki S, Mazur G, Kaplan P, Steurer M, Schuh A, Montillo M, Kryachok I, Middeke JM, Kulyaba Y, Rekhtman G, Gorczyca M, Daly S, Chang CN, Lisby S, Gupta I. Phase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leuk Lymphoma 2016; 57:2037-46. [DOI: 10.3109/10428194.2015.1122783] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
17
|
Stepanishyna I, Kryachok I, Titorenko I, Filonenko K, Martynchyk A, Novosad O, Sokolov V, Vereschako R. Intermediate Results of Treatment of Primary Mediastinal Large В-Cell Lymphoma with Da-Epoch-R Regimen. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu339.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Abramenko I, Bilous N, Chumak A, Davidova E, Kryachok I, Martina Z, Nechaev S, Dyagil I, Bazyka D, Bebeshko V. Chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chernobyl NPP accident—With focus on immunoglobulin heavy chain gene analysis. Leuk Res 2008; 32:535-45. [PMID: 17897714 DOI: 10.1016/j.leukres.2007.08.013] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2007] [Revised: 08/19/2007] [Accepted: 08/20/2007] [Indexed: 01/22/2023]
Abstract
Clinical data and immunoglobulin variable heavy chain (IgVH) gene configuration were analyzed in 47 CLL patients, exposed to ionizing radiation (IR) due to Chernobyl NPP accident, and 141 non-exposed patients. Clean-up workers of the second quarter of 1986 (n=19) were picked out as separate group with the highest number of unmutated cases (94.4%), increased usage of IgVH1-69 (33.3%) and IgVH3-21 (16.7%) genes, high frequency of secondary solid tumors (6 cases) and Richter transformation (4 cases). These preliminary data suggest that CLL in the most suffered contingent due to Chernobyl NPP accident might have some specific features.
Collapse
Affiliation(s)
- Iryna Abramenko
- Research Centre for Radiation Medicine, Academy of Medical Sciences of Ukraine, Kyiv, Ukraine.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Abramenko I, Bilous N, Kryachok I, Filonenko I, Pilipenko G, Chumak A, Bazyka D, Bebeshko V. IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine. Exp Oncol 2007; 29:226-230. [PMID: 18004251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
UNLABELLED THE AIM of the study was to evaluate the frequency of IGHV3-21 gene usage and its clinical significance for patients with B-cell chronic lymphocytic leukemia (CLL) in Ukraine. PATIENTS AND METHODS Immunoglobulin variable heavy chain (IGHV) gene repertoire was studied in 189 CLL patients using reverse transcribed polymerase chain reaction and direct sequence of amplified products. RESULTS IGHV3-21 gene expression was found in 11 cases (5.8%), and its frequency was intermediate between Scandinavian (11.7%) and Mediterranean CLL (2.9%) cohorts. The most of cases (9 of 11) belonged to subset with heterogeneous HCDR3 (heteroHCDR3 subset), and only 2 cases--to subset with classical short ARDANGMDV motif (homHCDR3 subset). Six IGHV3-21 cases were mutated and 5 cases were unmutated. All unmutated cases (all were from heteroHCDR3 subset) had similarity of their HCDR3s with previously published sequences. The differences in overall (OS), progression-free (PFS) and treatment-free survival (TFS) for IGHV3-21 positive patients in comparison with CLL patients expressing the other IGHV genes were statistically insignificant. These survival parameters were comparable also for CLL patients with mutated IGHV3-21 gene usage and expression the others mutated IGHV genes. But remarkable feature of IGHV3-21 expressing patients was high incidence of solid tumors. They have developed in 4 IGHV3-21 positive cases (36.4%) and in 10 cases with expression of the others IGHV genes (5.6%, p=0.0002). Furthermore, in small group of 6 patients with mutated IGHV3-21 gene expression, 3 patients had solid tumors and one underwent Richter transformation. Unmutated IGHV3-21 gene expressed patients had worse OS and PFS in comparison with CLL patients that expressed the others unmutated IGHV genes. CONCLUSION Presented data are in agreement with the opinion about negative prognostic significance of IGHV3-21 gene expression regardless its mutation status. IGHV3-21 expression was associated with development of secondary solid tumors. Revealed high level of homology in heteroHDR3s subset might suggest about possible antigenic influence also, in addition to homHCDR3 subset that was proposed earlier.
Collapse
MESH Headings
- Adult
- Aged
- Amino Acid Sequence
- Female
- Flow Cytometry
- Gene Expression
- Gene Rearrangement, B-Lymphocyte, Heavy Chain
- Genes, Immunoglobulin Heavy Chain
- Humans
- Immunoglobulin Variable Region/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Male
- Middle Aged
- Molecular Sequence Data
- Mutation
- Neoplasms, Second Primary/genetics
- Prognosis
- Reverse Transcriptase Polymerase Chain Reaction
- Sequence Homology, Amino Acid
- Ukraine
Collapse
Affiliation(s)
- I Abramenko
- Scientific Centre for Radiation Medicine Academy of Medical Science of Ukraine, Kiev, Ukraine
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Bilous N, Abramenko I, Kryachok I, Bazyka D, Chumak A, Bebeshko V. Significance of VH genes mutation status for prognosis of CLL patients. Exp Oncol 2005; 27:325-9. [PMID: 16404355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
AIM The aim of this study was to evaluate significance of VH mutation status for prognosis of B-cell chronic lymphocytic leukemia (B-CLL) patients in comparison with other prognostic markers. MATERIALS AND METHODS The VH mutation status was evaluated in 43 B-CLL patients by RT-PCR amplification and nucleotide sequencing, and CD38 expression - by two-color FACS analysis. The prognostic influence of VH mutation rate and CD38 expression level was tested by different statistical methods. RESULTS The increasing number of advanced cases over the follow-up period, shorter median time from diagnosis to start of second line therapy, worse response to fludarabine treatment, poor survival for early stages B-CLL were found in unmutated versus mutated CLL patients. The significance of CD38 expression for CLL prognosis was revealed as predictor for response for fludarabine treatment and time of progression in advanced stages. The correlation between CD38 expression and VH mutation status was not found. CONCLUSION Simultaneous determination of VH mutation status and CD38 expression may be helpful for prediction of CLL prognosis.
Collapse
MESH Headings
- ADP-ribosyl Cyclase 1/biosynthesis
- Adult
- Aged
- Antineoplastic Agents/therapeutic use
- Biomarkers, Tumor/analysis
- Female
- Flow Cytometry
- Humans
- Immunoglobulin Heavy Chains/genetics
- Immunoglobulin Variable Region/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Male
- Middle Aged
- Mutation
- Prognosis
- Reverse Transcriptase Polymerase Chain Reaction
- Vidarabine/analogs & derivatives
- Vidarabine/therapeutic use
Collapse
Affiliation(s)
- N Bilous
- Scientific Research Centre for Radiation Medicine, AMS of Ukraine, Kyiv, Ukraine.
| | | | | | | | | | | |
Collapse
|